Sumitomo Pharma Co., Ltd. DNPUF
11.91 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
10.50 Day range 10.50
8.41 52-week range 19.20
- YTD
- -17.06%
- 1 year
- +8.37%
- Market cap
- 5.34B
- EPS (ttm)
- 0.67
- P/E ratio
- 17.78
- YTD return
- -17.06%
- 1-year return
- +8.37%
- Volume
- 118
- Avg volume
- 56
- Open
- 10.50
- Previous close
- 11.91
- Day's range
- 10.50 – 10.50
- 52-week range
- 8.41 – 19.20
- Earnings date
- Nov 4, 2026
2Y +7.61 (+176.98%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.1248.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.1248 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.1176 | 0.2399 | +0.12 | +104.00% |
| May 13, 2026 | Mar 31, 2026 | -0.09599 | -0.01285 | +0.08 | +86.61% |
| Jan 30, 2026 | Dec 31, 2025 | -0.00555 | 0.1416 | +0.15 | +2,651.35% |
| Oct 31, 2025 | Sep 30, 2025 | 0.534 | 1.49 | +0.96 | +179.03% |
| Jul 31, 2025 | Jun 30, 2025 | 0.1368 | 0.1957 | +0.06 | +43.06% |
News
Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting 
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia 
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript 
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Your note
Sign in to keep a note on DNPUF — it syncs with the Stock Master app.